期刊文献+

前列腺癌组织中OPN和Survivin表达与PSA的相关性分析 被引量:6

The analysis of the correlation PSA and between expression of OPN and Survivin in prostate cancer tissue
在线阅读 下载PDF
导出
摘要 目的通过分析桥蛋白(OPN)和Survivin在前列腺癌(PCa)组织中的阳性表达与前列腺特异性抗原(PSA)的相关性分析,探究前列腺癌的预后判断方法。方法检测70例前列腺癌和48例前列腺增生组织应用免疫组织化学方法相关蛋白OPN、Survivin蛋白的表达和相应患者血浆中PSA值。结果前列腺癌组织中OPN和Survivin蛋白的阳性表达率分别51.4%(36/70)、65.7%(46/70),OPN和Survivin在前列腺增生组织中的阳性表达率分别10.4%(5/48)、0(0/48),在前列腺增生和前列腺癌组织组织中OPN和Survivin蛋白阳性表达率差异具有统计学意义(P<0.05),Survivin与OPN在前列腺癌组织中的阳性表达呈负相关(P<0.01)。OPN和Survivin蛋白表达和PSA数值与前列腺癌病理分级、临床分期、转移情况有关,具有统计学意义(P<0.05)。结论在临床上检测OPN、Survivin表达和前列腺特异抗原(PSA),对前列腺癌疾病的预后有作用。 Objective By means of detecting the analysis of the correlation PSA and between expression of OPN and Survivin in prostate cancer tissue we want to investigate the methods of therapy to PCa.Methods Immunohistochemistry was employed to measure the expression of OPN and Survivin cases of prostatic cancer and 48 cases benign prostatic hyperplasia and PSA in plasma.Results In prostatic cancer tissue,the positive expression rates of OPN and Survivin were 51.4%(36/70)、and 65.7%(46/70).In benign prostatic hyperplasia tissue,the positive expression rates of OPN and Survivin were 10.4%(5/48)、0(0/48),The positive expression of OPN and survivin between prostatic cancer and benign prostatic hyperplasia were significantly different(P〈0.05).The positive expression of OPN and survivin were related with the histologic grade,clinical stage and metastasis of prostatic cancer and PSA(P〈0.05).The expression of survivin was a reverse correlation with OPN expression in prostatic cancer(P〈0.01).Conclusion The detection expression of OPN and Survivin and PSA in PCa may help to offer a new mode for the prevention and treatment of prostatic cancer.
出处 《中国实验诊断学》 2016年第3期392-395,共4页 Chinese Journal of Laboratory Diagnosis
基金 内蒙古自治区高等学校科学研究项目(NJZY13173) 2015年内蒙古自治区自然科学基金面上项目(2015MS0877) 内蒙古民族大学自然科技基金培育项目(NMDGY1438)
关键词 前列腺癌 OPN SURVIVIN 前列腺特异性抗原 prostatic cancer OPN survivin PSA
  • 相关文献

参考文献10

  • 1Hoffinan KE,Chen MH, Moran BJ, et al. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate eancer[J]. Cancer, 2010,22(3) : 205.
  • 2Macrl A, Versaci A, Lupo G, et al. Role of osteopontin in breast cancer patients[J]. Tumor, 2010,95 (1) : 48.
  • 3李欣,汪娜,张彦,张舜欣,林倩,唐杰.端粒酶逆转录酶与血管内皮细胞生长因子在前列腺癌中的表达及其相关性的研究[J].中华男科学杂志,2005,11(10):724-726. 被引量:10
  • 4Senger DR,Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins [J]. Cell, 1979, 16 (4) :885.
  • 5Ambrosini G, Adida C, Aleteri DC, et al. A novel anti-apoptosis gene,survivin, expressed in cancer and lymphoma[J]. Nat Med, 1997,3:917.
  • 6Jain A, McKnight DA, Fisher LW, et al. Small integrin-birMing- proteins as serum markers for prostate cancer detection [J].. Clin- Cancer Res, 2009,15(16) : 5199.
  • 7Patil UD, Ragavan A, Nadaraj, et al. Helical CT angiographyi- nevaluation of live kidney donors [J]. Nephrol DialTr'anSplant, 2010,16(9) :1900.
  • 8Lewis GR,Mulcahy K, Brook NR .et al. A prospective study of the predictive power of spiral computed tomographic angiography for defining renal vascular anatomy before live-donor nephrecto- my[J]. BJU Int,2011,94 (7) :1077.
  • 9Stokkel MP, Zwinderman AH, Zwartendijk J, et al. The value of pretreatment clinical and biochemical parameters in staging and prognostic stratification of patients with newly di- agnosed pros- tate carcinoma[J]. Int J Biol Markers, 1998,13 (2) :70.
  • 10Suzuki A, HoT, Kawano H, et al. Survivin Initiates Procaspase3/p21 Complex Format ion as a Result o{ Interaction with CDK4 to Resist Fas Mediated Cell Death[J]. Oncogene, 2000,19 (10) : 1346.

二级参考文献16

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1370
  • 2Jemal A, Murray T, Samules A, et al. Cancer Statistics, 2003[J]. CA Cancer J Clin, 2003, 53 ( 1 ) :5-26.
  • 3Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity[ J ]. EMBO J, 1992,11(5) :1921-1929.
  • 4Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen [ J]. Science,1989, 246(4935 ): 1306-1309.
  • 5Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor ( vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract [ J ].Cancer Res, 1993, 53(19) :4727-4735.
  • 6Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma[J]. J Natl Cancer Inst, 1995, 87(7) :506-516.
  • 7Yoshiji H, Gomez DE, Shibuya M, et al. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer [ J]. Cancer Res, 1996, 56 (9):2013-2016.
  • 8Hao XP, Willis JE, Pretlow TG, et al. Loss of fragile histidine traid expression in colorectal carcinomas and premalignant lesions [J]. Cancer Res, 2000, 60(1) :18-21.
  • 9Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human [ J ]. Science, 1997, 277(5328) :955-959.
  • 10Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas[J]. Nat Genet, 1998, 18(1):65-68.

共引文献9

同被引文献76

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部